Alumis
San Francisco
About Alumis
Alumis develops precision medications to treat autoimmune illnesses. The company's analytics platform and understanding of immunologic disorders aid in the development of treatments and medications for autoimmune diseases, allowing patients to alleviate suffering and modify their way of life.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $917.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:ALMS
- Website: alumis.com
- Phone: +1- 650-231-6625
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/alumis-22589 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.